Skip to Content
Merck
All Photos(2)

Key Documents

Safety Information

RAB0050

Sigma-Aldrich

Human TARC / CCL17 ELISA Kit

for serum, plasma, cell culture supernatant and urine

Synonym(s):

C-C motif chemokine 17 , CC chemokine TARC, CCL17, TARC

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41116158
NACRES:
NA.32

species reactivity

human

packaging

kit of 96 wells (12 strips x 8 wells)

technique(s)

ELISA: suitable
capture ELISA: suitable

input

sample type urine
sample type serum
sample type cell culture supernatant(s)
sample type plasma

assay range

inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 5 pg/mL
standard curve range: 10.2-2500 pg/mL

detection method

colorimetric

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... CCL17(6361)

General description

The Human TARC (Thymus and Activation Regulated Chemokine) ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human TARC in serum, plasma, cell culture supernatants and urine.

Immunogen

Recombinant Human TARC

Application

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

Biochem/physiol Actions

C-C motif chemokine ligand 17 (CCL17), also known as thymus and activation-regulated chemokine (TARC), is produced by bronchial epithelial cells, endothelial cells and myeloid dendritic cells. This chemokine is a ligand for CC chemokine receptors 4 and 8. It is involved in recruiting type 2 T-helper cells (Th2) cells and in activating other antigen-presenting cells. CCL17 has been linked to atopic dermatitis and asthma.

Other Notes

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

Kit Components Also Available Separately

Product No.
Description
SDS

  • RABELADBELISA 5X Assay/Sample Diluent Buffer B (Item E1)SDS

  • RABELADCELISA 1X Assay/Sample Diluent Buffer C (Item L)SDS

  • RABSTOP3ELISA Stop Solution (Item I)SDS

  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)SDS

  • RABWASH420X Wash Buffer (Item B)SDS

Pictograms

Corrosion

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Met. Corr. 1

Storage Class Code

8A - Combustible, corrosive hazardous materials

WGK

WGK 3


Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

PDSCL

Please refer to KIT Component information

PRTR

Please refer to KIT Component information

FSL

Please refer to KIT Component information

ISHL Indicated Name

Please refer to KIT Component information

ISHL Notified Names

Please refer to KIT Component information

Cartagena Act

Please refer to KIT Component information

JAN Code

キットコンポーネントの情報を参照してください


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma
Ying Xiong
BMC Cancer (2017)
Targeting CD1c-expressing classical dendritic cells to prevent thymus and activation-regulated chemokine (TARC)-mediated T-cell chemotaxis in rheumatoid arthritis
MR Hillen
Scandinavian Journal of Rheumatology. Supplement (2017)
Anna Guidetti et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(22), 5641-5651 (2014-09-23)
To evaluate safety and activity of perifosine and sorafenib combination therapy in patients with lymphoproliferative diseases. Patients with relapsed and refractory lymphoproliferative diseases received perifosine (50 mg twice daily) for 1 month. Patients achieving less than partial response (PR) after
Karen Knipping et al.
Acta paediatrica (Oslo, Norway : 1992), 103(7), 766-774 (2014-04-05)
Eosinophilic oesophagitis (EO) is an emerging worldwide disease, closely associated with male gender and allergic disorders. This study investigated the distribution of allergy markers in a cohort of children with EO. We analysed allergy markers in 91 children (62 males

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service